Press Releases Apr 24, 2024 Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 Mar 04, 2024 Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva Feb 29, 2024 Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress View all press releases Presentations & Events View all presentations & events Form 8937 View Form 8937 - September 30, 2015 View Form 8937
Apr 24, 2024 Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Feb 29, 2024 Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress